Menu
Search
|

Menu

Close
X

Pulmatrix Inc PULM.OQ (NASDAQ Stock Exchange Global Market)

1.45 USD
-0.03 (-2.03%)
As of Feb 22
chart
Previous Close 1.48
Open 1.50
Volume 18,954
3m Avg Volume 52,930
Today’s High 1.50
Today’s Low 1.42
52 Week High 4.75
52 Week Low 1.35
Shares Outstanding (mil) 20.12
Market Capitalization (mil) 43.07
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
1
FY15
2
EPS (USD)
FY17
-0.714
FY16
-1.879
FY15
-1.875
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
241.95
5.77
Price to Book (MRQ)
vs sector
2.73
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
28.81
16.52
LT Debt to Equity (MRQ)
vs sector
11.43
12.22
Return on Investment (TTM)
vs sector
-104.24
14.43
Return on Equity (TTM)
vs sector
-122.80
16.13

EXECUTIVE LEADERSHIP

Mark Iwicki
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Robert Clarke
Chief Executive Officer, Director, Since 2015
Salary: $220,635.00
Bonus: $115,500.00
William Duke
Chief Financial Officer, Since 2015
Salary: $160,385.00
Bonus: $91,250.00
David Hava
Chief Scientific Officer, Since 2012
Salary: $163,327.00
Bonus: $64,125.00
Jean Sung
Vice President - Pharmaceutical Development, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

99 Hayden Ave Ste 390
LEXINGTON   MA   02421-7966

Phone: +1781.3572333

Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.

SPONSORED STORIES